Veronica Hood

About Veronica Hood

This author has not yet filled in any details.
So far Veronica Hood has created 18 blog entries.

DSF Announces 2020 Grant Recipients

By |2020-12-04T01:56:47-05:00December 4th, 2020|Categories: Decoding Dravet Blog|

The Dravet Syndrome Foundation (DSF) announced the 2020 grant awardees last night at the 11th annual Research Roundtable. DSF is excited to be funding two 2-year research grants and an additional 1-year postdoctoral fellowship. Following this year’s awards, DSF’s total contribution to research projects will be nearly $5 million. The first of the 2-year grants [...]

The impact of COVID-19 in Dravet Syndrome: a UK survey

By |2020-11-10T10:26:47-05:00November 10th, 2020|Categories: DSF Research Review|Tags: , , , |

The COVID-19 pandemic has raised health concerns worldwide, but particularly in communities that may be at higher risk from illness and infection. To understand this better in the Dravet syndrome community, Dravet Syndrome UK (DSUK) performed a survey of families caring for an individual living with Dravet syndrome from June-July 2020 to assess the impacts [...]

Lorcaserin Enters Clinical Trials for Dravet Syndrome

By |2020-10-15T23:42:42-05:00October 16th, 2020|Categories: Decoding Dravet Blog|

Serotonin (5-HT) signaling has been a major focus of drug development targeting seizures in Dravet syndrome (DS) in recent years. For example, the community recently saw the FDA-approval of Fintepla (fenfluramine) as an adjunctive (add-on) therapy for DS. Fenfluramine had been a known anti-epileptic agent since the 1980’s, particularly utilized in Europe, but its marketing [...]

ENVISION: A 2-year observational study of Dravet syndrome

By |2020-09-17T22:26:32-05:00September 18th, 2020|Categories: Decoding Dravet Blog|

The Dravet syndrome community has long been awaiting gene therapy approaches to provide true disease-modifying treatments. We now watch optimistically as new therapies are in final stages of pre-clinical development or are beginning early-phase clinical trials. One of the challenges of these types of gene-based therapies entering human clinical trials is that a placebo-control approach [...]

EpyGenix Launches Phase II Trial for EPX-100

By |2020-09-07T00:12:10-05:00September 4th, 2020|Categories: Decoding Dravet Blog|

EpyGenix Therapeutics, in partnership with Greenlight Clinical, is currently enrolling a Phase II, multicenter, randomized, double-blind, placebo-control clinical trial for EPX-100 (Clemizole Hydrochloride, oral solution) in children diagnosed with Dravet syndrome. In January 2020, Epygenix announced the completion of Phase I trials for EPX-100, establishing the safety of EPX-100 in healthy subjects and clearing the [...]

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome.

By |2020-09-08T18:24:56-05:00September 4th, 2020|Categories: DSF Research Review|Tags: , , , |

Just last month, a previous research review detailed how Stoke Therapeutics developed their targeted augmentation of nuclear gene output (TANGO), utilizing anti-sense oligonucleotides (ASOs) to upregulate expression of several genes, including SCN1A, in human cells and mouse brain. ASOs are single-stranded RNAs that bind to target RNA sequences and have the potential to alter the [...]

Focal epilepsy in SCN1A-mutation carrying patients: is there a role for epilepsy surgery?

By |2020-08-23T23:03:55-05:00August 28th, 2020|Categories: DSF Research Review|Tags: , , , |

In this brief report published in June, Vezyroglou et al detail the results of epilepsy surgery for focal seizures in 8 patients carrying mutations in the SCN1A gene that were predicted to be causal. Three of the 8 patients had a clinical diagnosis of Dravet syndrome. The surgical procedures were successful in reducing or eliminating [...]

Electrophysiological alterations of pyramidal cells and interneurons of the CA1 region of the hippocampus in a novel mouse model of Dravet syndrome

By |2020-08-24T12:16:38-05:00August 24th, 2020|Categories: DSF Research Review|Tags: , , , |

In this paper, Dyment et al detail a new mouse for the study of Dravet syndrome modeled after a patient mutation. This particular mutation (H939R) does not result in the typical haploinsufficiency where Nav1.1 sodium channel levels are reduced, but rather appears to affect the function of one copy of the sodium channel. Consistent with [...]

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study

By |2020-08-24T12:35:41-05:00August 24th, 2020|Categories: DSF Research Review|Tags: , , , |

FINTEPLA (fenfluramine) was recently approved by the FDA for the treatment of seizures in Dravet syndrome. The FDA required Zogenix, Inc to include a black box warning on the label because fenfluramine belongs to a class of drugs that affect a specific serotonin receptor (5-HT2B), and these types of drugs have previously been associated with valvular [...]

Go to Top